News & Updates
Filter by Specialty:
Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC
A network meta-analysis (NMA) reports that the combination regimen comprising atezolizumab and bevacizumab appears to be better than other first-line systemic therapeutic alternatives for advanced hepatocellular carcinoma (HCC) in terms of providing a balance between overall survival (OS) benefit and quality of life (QoL) preservation.
Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC
05 Jun 2025
Antiviral therapy lowers HCC risk in indeterminate CHB phase
Patients with chronic hepatitis B (CHB) in the indeterminate phase are predisposed to advanced liver disease and hepatocellular carcinoma (HCC), as shown by a systematic review and meta-analysis.
Antiviral therapy lowers HCC risk in indeterminate CHB phase
27 May 2025
Linerixibat quells cholestatic itch in PBC, enabling better sleep
The ileal bile acid transporter inhibitor linerixibat provides rapid and substantial relief from cholestatic pruritus, in turn reducing associated sleep disturbances, in patients with primary biliary cholangitis (PBC), as shown in the global, phase III GLISTEN trial.
